Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Sharma, Tanvi [VerfasserIn]   i
 Schwalbe, Edward C. [VerfasserIn]   i
 Williamson, Daniel [VerfasserIn]   i
 Sill, Martin [VerfasserIn]   i
 Hovestadt, Volker [VerfasserIn]   i
 Mynarek, Martin [VerfasserIn]   i
 Rutkowski, Stefan [VerfasserIn]   i
 Robinson, Giles W. [VerfasserIn]   i
 Gajjar, Amar [VerfasserIn]   i
 Cavalli, Florence M. G. [VerfasserIn]   i
 Ramaswamy, Vijay [VerfasserIn]   i
 Taylor, Michael D. [VerfasserIn]   i
 Lindsey, Janet C. [VerfasserIn]   i
 Hill, Rebecca M. [VerfasserIn]   i
 Jäger, Natalie [VerfasserIn]   i
 Korshunov, Andrey [VerfasserIn]   i
 Hicks, Debbie [VerfasserIn]   i
 Bailey, Simon [VerfasserIn]   i
 Kool, Marcel [VerfasserIn]   i
 Chavez, Lukas [VerfasserIn]   i
 Northcott, Paul A. [VerfasserIn]   i
 Pfister, Stefan [VerfasserIn]   i
 Clifford, Steven C. [VerfasserIn]   i
Titel:Second-generation molecular subgrouping of medulloblastoma
Titelzusatz:an international meta-analysis of Group 3 and Group 4 subtypes
Verf.angabe:Tanvi Sharma, Edward C. Schwalbe, Daniel Williamson, Martin Sill, Volker Hovestadt, Martin Mynarek, Stefan Rutkowski, Giles W. Robinson, Amar Gajjar, Florence Cavalli, Vijay Ramaswamy, Michael D. Taylor, Janet C. Lindsey, Rebecca M. Hill, Natalie Jäger, Andrey Korshunov, Debbie Hicks, Simon Bailey, Marcel Kool, Lukas Chavez, Paul A. Northcott, Stefan M. Pfister, Steven C. Clifford
E-Jahr:2019
Jahr:10 May 2019
Umfang:18 S.
Teil:volume:138
 year:2019
 number:2
 pages:309-326
 extent:18
Fussnoten:Gesehen am 27.01.2020
Titel Quelle:Enthalten in: Acta neuropathologica
Ort Quelle:Berlin : Springer, 1961
Jahr Quelle:2019
Band/Heft Quelle:138(2019), 2, Seite 309-326
ISSN Quelle:1432-0533
Abstract:In 2012, an international consensus paper reported that medulloblastoma comprises four molecular subgroups (WNT, SHH, Group 3, and Group 4), each associated with distinct genomic features and clinical behavior. Independently, multiple recent reports have defined further intra-subgroup heterogeneity in the form of biologically and clinically relevant subtypes. However, owing to differences in patient cohorts and analytical methods, estimates of subtype number and definition have been inconsistent, especially within Group 3 and Group 4. Herein, we aimed to reconcile the definition of Group 3/Group 4 MB subtypes through the analysis of a series of 1501 medulloblastomas with DNA-methylation profiling data, including 852 with matched transcriptome data. Using multiple complementary bioinformatic approaches, we compared the concordance of subtype calls between published cohorts and analytical methods, including assessments of class-definition confidence and reproducibility. While the lowest complexity solutions continued to support the original consensus subgroups of Group 3 and Group 4, our analysis most strongly supported a definition comprising eight robust Group 3/Group 4 subtypes (types I-VIII). Subtype II was consistently identified across all component studies, while all others were supported by multiple class-definition methods. Regardless of analytical technique, increasing cohort size did not further increase the number of identified Group 3/Group 4 subtypes. Summarizing the molecular and clinico-pathological features of these eight subtypes indicated enrichment of specific driver gene alterations and cytogenetic events amongst subtypes, and identified highly disparate survival outcomes, further supporting their biological and clinical relevance. Collectively, this study provides continued support for consensus Groups 3 and 4 while enabling robust derivation of, and categorical accounting for, the extensive intertumoral heterogeneity within Groups 3 and 4, revealed by recent high-resolution subclassification approaches. Furthermore, these findings provide a basis for application of emerging methods (e.g., proteomics/single-cell approaches) which may additionally inform medulloblastoma subclassification. Outputs from this study will help shape definition of the next generation of medulloblastoma clinical protocols and facilitate the application of enhanced molecularly guided risk stratification to improve outcomes and quality of life for patients and their families.
DOI:doi:10.1007/s00401-019-02020-0
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1007/s00401-019-02020-0
 DOI: https://doi.org/10.1007/s00401-019-02020-0
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Biomarkers
 Medulloblastoma
 Meta-analysis
 Methylation
 Subtypes
K10plus-PPN:1688537651
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68480819   QR-Code
zum Seitenanfang